Tapentadol: review of adverse drug reactions reported to Eudravigilance.
Abstract
Background: Adverse drug reactions (ADRs) are a public health problem. Tapentadol is a novel opioid analgesic with a dual mode of action that was approved for acute and chronic pain. This drug has been associated with several ADRs, particularly involving Nervous System Disorders, Psychiatric Disorders, Gastrointestinal Disorders, and General Disorders and Administration Site Condition.
Objective: Since published studies on tapentadol-associated ADRs are limited, the major aim of this study was to characterise ADRs’ reports related to tapentadol included in EudraVigilance (EV).
Methods: The data analysed was retrieved from EV - the European database of suspected ADR reports, between January 1st, 2017 and October 17th, 2019. The ADR reports in which tapentadol was not the only reported drug of interest were excluded. We selected 865 cases from a total of 1467 reports identified.
Results: Within the selected ADR reports, the majority referred to cases involving adults. A predominance of female ADR reports (64.05%) was also observed. The five most frequent ADRs reported were nausea (9.36%), dizziness (9.25%), vomiting (4.86%), confusional state (4.62%) and headache (4.51%). Eight cases of serotonin syndrome were reported. Most patients recovered completely. Fatal outcomes were shown to be rare (2.66%).
Conclusions: Pharmacovigilance databases are important tools to evaluate the safety and efficacy profiles of drugs, thus improving patients’ safety and quality of life.
Despite an overall safety profile, the prescription of tapentadol still demands for caution and ongoing monitoring, in order to decrease its known and potential associated ADRs.
Copyright (c) 2021 Adela Iutis
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
When submitting an article to the Journal of Statistics on Health Decision (JSHD), authors certify the following clauses:
- Originality and single submission – The contents presented in the article have not been published previously in whole or in part, and were not submitted or are not under active consideration elsewhere prior JSHD decision. The article is authentic and does not contain plagiarism.
- Authorship – All authors reviewed the article, agreed with its content, and agreed to its submission to the JSHD. All the authorship criteria stated by The International Committee of Medical Journal Editors Guidelines were met.
- Conflicts of interest – Any conflict of interests were declared. If authors have no declaration, it should be written (in the acknowledgements section): “The authors declare no conflict of interests”.
- Ethics committee and informed consent (if applicable) – The current research was approved by an independent ethics committee and subjects gave their informed consent before they were enrolled in the study.
- And authors agree to the Open Access license agreement of the Journal of Statistics on Health Decision, stated bellow.
